AUTHOR INDEX Ferrannini, E. see Solini, A. Hultcrantz, R2. see Ormarsdottir, S. Fioretto, P. see Solini, A. Hultdin, J., Thogersen, A.M., Jansson, J.-H., Nilsson, T.K., Fontana, D. see Coppola, A. Weinehall, L. & Hallmans, G. Elevated plasma homocysteine: Forli, L., Halse. J., Haug, E., Bjortuft, 0., Vatn, M., Kofstad, J. & cause or consequence of myocardial infarction?, 491 30e, J. Vitamin D deficiency, bone mineral density and weight Hulthe, J. see Wallenfeldt. K. in patients with advanced pulmonary disease, 56 Hurme, M. see Maury, C.P.J. Fratiglioni, L. see Winblad, B. Hurt-Camejo, E. see Leinonen, E.S Fujii, H. see Sato, T. Fukuchi, Y. see Sato, T. Imbert, B. see Labarere, J. Irjala, K. see Waseén, E. Gansevoort, R.T. see Verhave, J.C. Isoaho, R. see Wasén, E. Gansevoort, R.T. see Wulffelé, M.G. Gareeboo, H. see Séderberg, S. Jack, C. see Winblad, B. Georgiades, A. see Janszky, | Jackson, S.L., Peterson, G.M.. Vial, J.H. & Jupe, D.M.L. Improving Giacobini, E. see Winblad, B. the outcomes of anticoagulation: an evaluation of home Giannini, E.G. & Testa, R. Reply to Farina ti et al.: classification of follow-up of warfarin initiation, 137 ‘intermediate stage’, untreated hepatocellular carcinoma Jansen, A.C.M., Aalst-Cohen, E.S., Tanck, M.W.., Trip, M.D. patients: the neighbour's grass is not so green, 531 Lansberg, P .J., Liem, A.H., Roeters van Lennep, H.W.O.., Giugliano, D. see Coppola, A Sijbrands, E.J.G. & Kastelein, J.J.P. The contribution of Glatthor, C. see Hausleiter, J. classical risk factors to cardiovascular disease in familial Gotzsche, P.C. see Hrobjartsson, A. hypercholesterolaemia: data in 2400 patients, 482 Graff, C. see Winblad, B. Janssen, W.M.T. see Verhave. J.C Graff-Iversen, S., Hammar, N., Thelle, D.S. & Tonstad, S$. Hormone Jansson, J.-H. see Hultdin, J. therapy and mortality during a 14-year follow-up of 14 32 Janszky, I., Ericson, M., Lekander, M.. Blom, M.. Buhlin, K.. Norwegian women, 43> 7 Georgiades, A. & Ahnve, S. Inflammatory markers and heart Grubb, A.O. see Christensson, A.G. rate variability in women with coronary heart disease, 421 Janzon, E., Hedblad, B., Berglund, G. & Engstrém, G. Tobacco and Hallmans, G. see Hultdin, J. myocardial infarction in middle-aged women: a study of Halse, J. see Forli, L. factors modifying the risk, 111 Hammar, N. see Graff-Iversen, S. Jarnerot, G. see Midhagen, G. Hamsten, A. see Bartnik, M. Jelic. V. see Winblad, B. Hansson, T. see Midhagen, G. Johansson, L. see Séderberg, S. Hardy, J. see Winblad., B. Johansson, P., Kutti, J.. Andréasson, B.. Safai-Kutti. S.. Vilén. | Hargrove, F. see Hulgan, T. Wedel, H. & Ridell. B. Trends in the incidence of chronic Haug, E. see Forli, L. Philadelphia chromosome negative (Ph-) myeloproliferative Hausleiter, J.. Kastrati, A., Mehilli, J.. Schithlen, H., Pache, J.. disorders in the city of Géteborg, Sweden, during 198 3-99, Dotzer, F., Glatthor, C., Siebert, S., Dirschinger, J., Schomig. 16] A. A randomized trial comparing phosphorylcholine-coated Jones. S. see Backman. L. stenting with balloon angioplasty as well as abciximab with de Jong, P.E. see Verhave, J.C. placebo for restenosis reduction in small coronary arteries, Jorm, A. see Winblad, B. 388 Juntikka. E.-L. see Luik, E. Hedblad. B. see Janzon. E. Jupe, D.M.L. see Jackson, S.L. Heikens, J.ebT:. see Stades, A.M.E. Heine, R.J. see Spijkerman, A.M.W. Kaarela, K. see Maury, C.P.]. Held, P. see Wilhelmsen, L. Kastelein, J.J.P. see Jansen, A.C.M. Henry, R.M.A. see Spijkerman, A.M.W. Kastrati, A. see Hausleiter, J. Hillege, H.L. see Verhave, J.C. Kerkman, D. see de Leon, M.J. Hino, O. see Sato, T. Kernodle, D.S. see Hulgan, T. Hiukka, A. see Leinonen, E.S. Kesadniemi, Y.A. see Santaniemi, M. Hoekstra, J.B.L. see Stades, A.M.E. Keynan, Y. & Pottesman. I. Neurological symptoms in a traveller Holleman, F. see Stades, A.M.E. returning from Central America, 174 Hollman. G., Ek, A.-C. & Olsson, A.G. Only one of four patients Kinra, S. & Davey Smith, G. Differential transmission of coronary with familial hypercholesterolaemia reach cholesterol treat- disease risk to offspring is not supported by evidence, 260 ment goals in primary prevention, 176 Kivela, S.-L. see Wasén, E. Holm, G. & Fagrell. B. Promotion of clinical science Key Kivipelto, M. see Winblad, B. Symposium series in the honour of Axel Key, a pioneer in Kofstad, J. see Forli, L. medicine, 179 Kooy. A. see Wulffelé, M.G. Holmberg, E. see Luik, E. Kors, J.A. see Spijkerman, A.M.W. Holmgren, G., Wikstrém, L., Lundgren, H.-E. & Suhr, O.B Kostense, P.J. see Spijkerman, A.M.W. Discordant penetrance of the trait for familial amyloidotic Krakau, I. see Eriksson, M polyneuropathy in two pairs of monozygotic twins, +53 Kumasaka, T. see Sato, T. Hrobjartsson, A. & Gotzsche, P.C. Is the placebo powerless? Update Kupari, M., Turto, H. & Lommi, J. Diagnosing heart failure in of a systematic review with 52 new randomized trials aortic valve stenosis. 381 comparing placebo with no treatment, 91 Kutti, J. see Johansson, P. Hulgan, T., Rosenbloom, S.T., Hargrove, F., Talbert, D.A., Kutti, J. see Luik, E. Arbogast, P.G., Bansal, P., Miller, R.A. & Kernodle, D.S. Oral quinolones in hospitalized patients: an evaluation of a computerized decision support intervention, 349 © 2004 Blackwell Publishing Ltd Journal of Internal Medicine 256: AUTHOR INDEX Labarere. J.. Bosson, J.-L., Br ].-P.. Fabre. M., Imbert, B.., Mehta, P.D. see de Leon, M.J. Carpentier, P. & Pernod, G. Validation of a clinical guideline Mezzatzsta, G. see Mule, G. on prevention of venous thromboembolism in medical Midhagen, G., Aberg, A.-K., Olcén, P., Jaérnerot. G., Valdimarsson, inpatients: a before-and-after study with systematic ultra- [., Dahlbom, I., Hansson, T. & Strém, M. Antibody levels in sound examination, 338 adult patients with coeliac disease during gluten-free diet: a aiho see Maury, C.P.J rapid initial decrease of clinical importance, 519 Laine. M.. Luukkainen, R. & Toivanen, A. Sindbis viruses and Miller, R.A. see Hulgan, T. other alphaviruses as cause of human arthritic disease, 45 Mongiovi. R. see Mule, G air, L. see '| eon, M.] Mule, G., Cottone, S., Vadala, A.. Volpe, V.. Mezzatesta, G. Lansberg see Jansen, A.C.M. Mongiovi, R., Piazza, G., Nardi, E., Andronico, G. & Cerasola, Lappas, G. see Wilhelmsen, | G. Relationship between albumin excretion rate and aortic Laukka., E.J. see Backman, I stiffness in untreated essential hypertensive patients, 22 Lavi, D. see Ofran, Y. Leinonen, E.S., Hiukka. A.. Hurt-Camejo, E.. Wiklund, O., Sarna Nadar, S.K., Blann, A.D. & Lip, G.Y.H. Plasma and platelet-derived S.S., Mattson Hultén, L.. Westerbacka, J.. Salonen. R.M. vascular endothelial growth factor and angiopoietin-1 in Salonen, J.T. & Taskinen. M.-R. Low-grade inflammation, hypertension: effects of antihypertensive therapy. 331 endothelial activation and carotid intima-media thickness in Naessén, T. see Ormarsdottir, S. type 2 diabetes, 119 Nannipieri, M. see Solini, A. Lekander, M. see Janszky, | Nardi, E. see Mule, G. de Leon, M.J.. DeSanti, S.. Zinkowski, R.. Mehta, P.D., Pratico, D.. Nasic, S. see Eliasson, M. Segal, S., Clark, C.. Kerkman, D., DeBernardis, J.. Li, J.. Lair, Navis. G.J. see Verhave, J.C L.. Reisberg, B.. Tsui. W. & Rusinek, H. MRI and CSF studies Niemela, K. see Vikman, S. in the early diagnosis of Alzheimer’s disease, 205 Niemela, M. see Vikman, S. Leosdottir, M., Nilsson, P., Nilsson, J.-A.. Mansson, H. & Berglund, Nieminen, M.S. see Vikman, S G. The association between total energy intake and early Nijpels, G. see Spijkerman, A.M.W. mortality: data from the Malm6 Diet and Cancer Study, 499 Nilsson, J. see Christensson, A.G Li. J. see de Leon. M.] Nilsson, J. . see Leosdottir, M Liem, A.H. see Jansen, A.C.M Nilsson . see Nilsson, P.M Liguori, E. see Coppola. A. Nilsson, P. see Fagerberg, B Liljestr6m, M. see Maury, C.P.J Nilsson, P. see Leosdottir, M. Lind, S., Olsson, A.G., Eriksson, M.. Rudling, M., Eggertsen, G Nilsson, P.M., Nilsson, J.-A. & Berglund, G. Reply to: Family & Angelin, B. Autosomal recessive hypercholesterolaemia: history of CVD: the mother-son link revisited, 261 normalization of plasma LDL cholesterol by ezetimibe in Nilsson, T.K. see Hultdin, J. combination with statin treatment, 406 Nilsson, T.K. see Marklund, N. Lip, G.Y.H. see Nadar, S.K. Nordberg, A. see Winblad, B. Lommi, J. see Kupari, M. Norhammar, A. see Bartnik, M. LOOf, L. see Ormarsdottir, S. Norrgren, K. see Christensson, A.G. Lowe, G.D.O. Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease, 361 Ofran, Y., Lavi. D., Opher, D., Weiss, T.A. & Elinav, E. Fatal Luik, E., Palk, K.. Everaus, H., Varik, M.. Aareleid. T.. Wennstrém, voluntary salt intake resulting in the highest ever docu- L., Juntikka, E.-L., Safai-Kutti, S., Stockelberg, D., Holmberg, mented sodium plasma level in adults (255 mmol L™’): a disorder linked to female gender and psychiatric disorders, E. & Kutti, J. The incidence and survival of acute de novo leukaemias in Estonia and in a well-defined region of western 525 Sweden during 1982-1996: a survey of patients aged > 65 Ohrvik, J. see Bartnik, M. Olcén, P. see Midhagen. G. years, 79 Lundgren, H.-E. see Holmgren, G. Oliviero, M. see Coppola, A. Luukkainen. R. see Laine, M. Olsson, A.G. see Hollman, G. Olsson, A.G. see Lind, S. Olsson, T. see Marklund, N. Majamaa-Voltti, K. see Vikman. S. Olsson, T. see S6derberg, S. Mallmin, H. see Ormarsdottir, S$ Opher, D. see Ofran, Y. Malmberg, K. see Bartnik. M Ormarsdottir, S., Mallmin. H., Naessén, T., Petrén-Mallmin, M., Mansson, H. see Leosdottir, M Broome, U., Hultcrantz, R. & LOOf, L. An open, randomized, Mantovani, A. see Simon. A controlled study of transdermal hormone replacement Marino, D. see Farinati, F. therapy on the rate of bone loss in primary biliary cirrhosis. Marklund, N.,. Peltonen, M.. Nilsson, T.K. & Olsson, T. Low and 63 high circulating cortisol levels predict mortality and cognitive dysfunction early after stroke, 15 Mattila, K. see Wasén, E. Pache, J. see Hausleiter, J. Mattson Hultén, L. see Leinonen, E.S. Palk, K. see Luik. E. Maury, C.P.J.. Liljestr6m, M., Laiho, K.. Tiitinen. S.. Kaarela, K. & Palmer, K. see Winblad, B. Hurme, M. Anaemia of chronic disease in AA amyloidosis is Passaro, A. see Solini, A. associated with allele 2 of the interleukin-1/-511 promoter Peltonen, M. see Marklund, N. gene and raised levels of interleukin-1/ and interleukin-18, Perneger, T. see Bernard Bagattini, S. 145 Pernod, G. see Labarere, J. van der Meer, J.W.M. see Bleijenberg, G. Perrier, A. see Bernard Bagattini. S. van der Meer, J.W.M. see Simon, A. Petersen, R.C. see Winblad, B. Mehilli, J. see Hausleiter, J. Petersen, R.C. Mild cognitive impairment as a diagnostic entity, 183 2004 Blackwell Publishing Ltd Journal of Internal Medicine 256: 532-536 AUTHOR INDEX Peterson, G.M. see Jackson, S.L. Solini, A., Passaro, A., Fioretto, P., Nannipieri, M. & Ferrannini. E. Petrén-Mallmin, M. see Ormarsdottir, S. Lipoprotein lipase gene variants and progression of nephro- Petrozzi, L. see Vassalle, C. pathy in hypercholesterolaemic patients with type 2 diabetes, Peuhkurinen, K. see Vikman, S. 30 Piazza, G. see Mule, G Spijkerman, A.M.W., Henry, R.M.A., Dekker, J.M.. Nijpels, G.. Pottesman, I. see Keynan, Y. Kostense, P.J., Kors, J.A.. Ruwaard, D., Stehouwer, C.D.A.. Pratico, D. see de Leon, M.J Bouter, L.M. & Heine, R.J. Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted Reisberg. B. see de Leon, M.J. screening and patients newly diagnosed in general practice: Ridell, B. see Johansson, P. the Hoorn Screening Study, 429 Ritchie, K. see Winblad, B. Stades, A.M.E., Heikens, J.T., Holleman, F. & Hoekstra, J.B.L. Ritt, M. Reply to: metformin — current restrictions should be Metformin — current restrictions should be alleviated, 358 alleviated, 359 Stegmayr, B. see Sdderberg, S. Rodu, B. see Eliasson, M. Stehouwer, C.D.A. see Spijkerman, A.M.W. Roeters van Lennep, H.W.O. see Jansen, A.C.M. Stehouwer, C.D.A. see Wulffelé, M.G. Rolandsson, O. What is the mechanism behind the association Stenlund, H. see Séderberg, S. between autoantibodies against GAD65 and high body mass Sterner, G. see Christensson, A.G. index?, 262 Stockelberg. D. see Luik, E. Rosenbloom, S.T. see Hulgan, T. Stouten, B. Chronic fatigue syndrome: a clinical and laboratory Rosengren, A. see Wilhelmsen, L. study with a well-matched control group, 265 Rudling, M. see Lind, S. Strdhle, A. & Wolters, M. Comment on the article ‘Genotype, Rusinek, H. see de Leon, M.]J. obesity and cardiovascular disease — has technical and social Ruwaard, D. see Spijkerman, A.M.W. advancement outstripped evolution?’, 86 Rydén, L. see Bartnik, M. Strom, M. see Midhagen, G. Suhr, O.B. see Holmgren, G. Sundkvist, G. see Christensson, A.G. Safai-Kutti, S. see Johansson, P Sundkvist, G. see Schdlin. A. Safai-Kutti, S. see Luik, E. Svardsudd, K. see Bjérkegren, K Salonen, J.T. see Leinonen, E.S. Svardsudd, K. see Eriksson, M. Salonen, R.M. see Leinonen, E.S. Santaniemi, M., Ukkola, O. & Kesaniemi, Y.A. Tyrosine phos- phatase 1B and leptin receptor genes and their interaction in lalbert, D.A. see Hulgan, T. type 2 diabetes, 48 Tanck, M.W. see Jansen, A.C.M. Sarna, S.S. see Leinonen, E.S. askinen, M.-R. see Leinonen, E.S. Sato, T., Seyama, K., Kumasaka, T., Fujii, H.. Setoguchi, Y., Tenerz, A. see Bartnik, M. Shirai, T., Tomino, Y., Hino, O. & Fukuchi, Y. A patient with ‘esta, R. see Giannini, E.G TSC1 germline mutation whose clinical phenotype was Thelle, D.S. see Graff-Iversen, S limited to lymphangioleiomyomatosis, 166 ‘hogersen, A.M. see Hultdin, J. Schélin, A. & Sundkvist, G. Reply to: what is the mechanism lierala, I. see Vikman, S behind the association between autoantibodies against ‘jitinen, S. see Maury. C.P.]J. GAD6S and high body mass index?, 264 Toivanen, A. see Laine, M. Schémig, A. see Hausleiter, J. ‘omino, Y. see Sato, T. Schiihlen, H. see Hausleiter, J. Tonstad, S. see Graff-Iversen. S. Segal, S. see de Leon, M.J. ‘revisani, F. see Farinati, F. Setoguchi, Y. see Sato, T. Trip, M.D. see Jansen, A.C.M. Seyama, K. see Sato, T. Tsui, W. see de Leon, M.J. Shaw, J. see S6derberg, S. ‘umber, M.B. & Dickersin, K. Publication of clinical trials: Shirai, T. see Sato, T. accountability and accessibility 27711 Tuomilehto, J. see Séderberg, S Siebert, S. see Hausleiter, J. Sijbrands, E.J.G. see Jansen, A.C.M. rurto, H. see Kupari, M. Silveira, A. see Bartnik, M. Tuunanen, H. see Vikman, S. Simon, A., Bijzet, J., Voorbij, H.A.M., Mantovani, A., van der Meer, J.W.M. & Drenth, J.P.H. Effect of inflammatory attacks Ukkola, O. see Santaniemi. M. in the classical type hyper-IgD syndrome on immunoglobin D, cholesterol and parameters of the acute phase response, Vadala, A. see Mule, G. 247 Vahlberg, T. see Wasén, E S. see Wehren, L.E. Valdimarsson, T. see Midhagen, G. Sjéstrom, L.-G. see Sdderberg, S. Varik, M. see Luik, E. Small, B.J. see Backman, L. Vassalle, C., Petrozzi, L., Botto, N., Andreassi. M.G. & Zucchelli. Séderberg, S., Stegmayr, B., Stenlund, H., Sjéstrém, L.-G., Agren, G.C. Oxidative stress and its association with coronary artery A., Johansson, L., Weinehall, L. & Olsson, T. Leptin, but not disease and different atherogenic risk factors, 308 adiponectin, predicts stroke in males, 128 Vatn, M. see Forli, L. Séderberg, S., Zimmet, P., Tuomilehto, J., de Courten, M., Dowse. Vercoulen, J.H.H.M. see Bleijenberg, G. G.K., Chitson, P., Stenlund, H., Gareeboo, H.. Alberti, Verhave, J.C., Hillege. H.L.. Burgerhof, J.G.M., Janssen, W.M.T., K.G.M.M. & Shaw, J. High incidence of type 2 diabetes and Gansevoort, R.T., Navis, G.J., de Zeeuw, D., de Jong. P.E. for increasing conversion rates from impaired fasting glucose the PREVEND study group. Sodium intake affects urinary and impaired glucose tolerance to diabetes in Mauritius, 37 albumin excretion especially in overweight subjects, 324 Vial, J.H. see Jackson, S.L. © 2004 Blackwell Publishing Ltd Journal of Internal Medicine 256: 532 AUTHOR INDEX Vikman, S., Airaksine Tierala, I., Peuhkurinen, K.. Westerbacka, J. see Leinonen, E.S. Majamaa-Voltti. K mela, M.. Tuunanen, H., Nieminen Wiklund, O. see Leinonen, E.S M.S. & Niemela. K. ywroved adherence to practice guidelines Wikstrand, J. see Wallenfeldt, K vields better out 1c in high-risk patients with acute Wikstrém, L. see Holmgren, G. coronary syndrome withot leva findings from Wilhelmsen, L., Held, P. & Wedel, H. Clinical trials: a summary, nationwide FINACS studies, 316 284 Johansson, P Wilhelmsen, L., Lappas, G. & Rosengren, A. Risk of coronary Winblad. B events by baseline factors during 28 years follow-up and fule. G three periods in a random population sample of men, 298 A.M. se ‘ Winblad, B., Palmer. K.. Kivipelto, M.. Jelic, V. & Fratiglioni, L. Introduction: Mild cognitive impairment: beyond controver- . towards a consensus, 181] K., Kivipelto, M.. Jelic. V.. Fratiglioni, L., Nordberg. A., Backman, L., Albert, M.., rai, H., Basun, H.. Blennow, K., De Leon, M.., Erkinjuntti, T., Giacobini, E., Graff, C., Hardy, J.. Jorm, A.. Ritchie, K., van Duijn. C., Visser, P. & ..C. Mild cognitive impairment - beyond contro- versies, towards a consensus: report of the International shiaalie ak aie ri as ye atinine-based formulae with Working Group on Mild Cognitive Impairment, 240 : Wolters. M. see Strdhle, A serum Wulffelé, M.G., Kooy, A., de Zeeuw, D., Stehouwer, C.D.A. & Gansevoort, R.T. The effect of metformin on blood pressure. lasma cholesterol and triglycerides in type 2 diabetes e mineral density: can Bi RAMOS ] ruments identify women 5 a j d}e Zeeuw Zimmet Zinkows Zuccnehe lli 2004 Blackwell Publishing Ltd Journal of Internal Medicine 256: 532-536 Journal of Internal Medicine 2004; 256: 537 Keyword index acute contiguous gene syndrome, idiopathic myelofibrosis, 161 coronary syndrome, 316 coronary immunoglobulin D, 247 de novo leukaemia, 79 artery disease, 308 >I SS impaired fasting glucose, 37 myocardial infarction, 288 circulation, 398 impaired glucose tolerance. 37, 288 phase response. 247 heart disease, 298, 361, implementation, 316 adiponectin, 128 cortisol, 15 incidence, 37, 79, 101, 161 adult height, 472 C-reactive protein, 421 inflammation, 119 ageing. 183 creatinine, 491, 510 INR monitoring. 137 albumin, 49] CVD. 119 interleukin-6, 421 alphaviruses, 457 cystatin C, 510 nterleukin-18, ] 145 \lzheimer’s disease, 18 interleukin-1 240 definition, 240 polymorphisms, 145 amyloidosis, 145, 453 dehydroepiandrosterone receptor antagonist, 42] anaemia of chronic disease, diabetes, 119, 288, 472 /-511 gene polymorphism, 145 angiopoietin-1, 331 mellitus, 37, 101 mic stroke, 15, 128 antibiotics, 349 nephropathy. 30 isoprostane, 308 antibody response, 5 diagnosis, 153 anticoagulation, 137 antioxidant, 398 GI1c rt 519 Karelian fev differential diagnosis aortic d1i sorientation, 15 stiffness, 22 Doppler echo-cardiography valve stenosis, 38] dysesthesia, 174 arterial hypertension, dyslipidaemia atheroma, 41 3 atherosclerosis, 308, 413 authorship, 271 ‘arly diagnosis, in lipase polymorphisms autosomal recessive hyper- dfuecara)t ion, 137a e cholesterolaemia, 406 ‘lectronic publishing. longitudinal. endothelium, 119 long-term follow-up, 298 epidemiology, 101, 429, 437 lymphangioleiomyomatosis, 166 balloon angioplasty, 388 essential thrombocythaemia, 161 B-amyloid, 224 Estonia, 79 biliary. 63 zetimibe, 406 biomarkers, 2 birth weight, 2 Mauritius blood pressure, familial hypercholesterolaemia. 406 MCI, 205, body family history, 298 memory, | composition ferritin, 247 meta-analysis, 1, 91 size, 254 filtration, 30 metab¢ syndrome bone fish poisoning. metiormin density. 63 folate. 446 methylmalonic acid, 446 mineral density, 56 forme fruste, 166 microalbuminuria, 2>2 . 20 , 524 mineral density testing, >3 75 mild cognitive impairment 183, 23 5 gene—gene interaction, 48 240 calcium channel blockers, 33 genetics, 453 Modification of Diet in Renal Disease caloric intake, 499 genetics and dementia, 235 formula, 70 cancer, 499 germline mutation, 166 mortality, 15, 499 cardiovascular, 499 glomerular, 30 MRI, 205 filtration rate, 70 multivariate analysis, 153 driisske,a se2,2 429 37,472. 482 glycoprotein II[b/IIla antagonists, 388 myeloproliferative disorders. 161 risk factor, 32 guidelines, 316 myocardial infarction, 111. 491 cerebrospinal fluid, 224 chemokines, 398 haemorrhage, 1 37 natriuretic peptides, 381 cholesterol. 1, 111 haemorrhagic stroke, 128 1ephropathy. 510 Ciguatera, 174 heart nested case-referent study. 128 Ciguatoxin, 174 failure, 381 neuropathy, 453 clinical rate variability. 421 criteria. 240 heparin, 338 obesity. 324 decision support systems, high density lipoprotein, 254 occupation and marital status, 111 trials, 271 homocysteine, 398, 446, 491 Ockelbo disease, 457 coagulation, 361 hormone oestrogen, 63 Cockcroft-Gault formula, 70 replacement therapy. ¢ oral, 525 coeliac disease, 519 treatment, 437 osteoporos: is, 63,2 3 cognition, 15, 195 hypercholesterolaemia. oxidative stress, 308 cohort studies, 37, 101 hyper-IgD syndrome, 247 conflict of interest, 271 hypernatraemia, 525 pain, 91 consensus, 240 hypertension, 111, 23 31 paresthesia, 174 © 2004 Blackwell Publishing Ltd KEYWORD INDEX pentraxin-3, 247 risk transition, 195 placebo effect, 91 assessment, 375 transplantation, 56 placebos, 91 determinants, 491 treatment trial, 446 platelet, 331, 388 factors, 128, 298, triglycerides, 1, 254 Pogosta disease, 457 stratification, 316 tuberous sclerosis complex, 166 polycystic kidney disease, 166 type 2 polycythaemia vera, 161 screening, 375, 429 diabetes. 30, 48, 429 population, 499 serum diabetes mellitus, 1 preclinical, 195 creatinine, 70 tyrosine phosphatase 1B,2 48 dementia. 240 cystatin C, 70 prediction rule, 153 Sindbis viruses. 457 ultrasonography, 413 prevalence, 101, 288 single nucleotide polymorphism, 48 urinary sodium excretion, 324 prevention, 338 pP-rsoeclaelcctiitno,n in,3 247 ssmmookkeilnegs,s , 1111] 01 vascular endothelial growth factor, 331 psychiatric, sodium, 525 venous thrombosis, 338, 361 publication bias, 27 statin, 406 viral arthritis, 457 publishing, 271 stents, 388 vitamin pulmonary stress, 298 B12, 446 disease. 56 ssturrovkiev,a l, 367] 9 D, 56 embolism, 153, 33 Sweden, 79 pulse wave velocity. symptoms, 446 warfarin, 137 systematic review, 1, 9] weight, 56 quinolones, 349 women, 111, 421 women’s health, 437 tau proteins, 224 renal function, 510 tobacco, 101 restenosis. 388 total antioxidant capacity, 308 2004 Blackwell Publishing Ltd Journal of Internal Medicine 256: 5